Study: Bone drug lowers breast cancer risk 38% in high-risk women - USATODAY.com
The osteoporosis drug Raloxifene was found to reduce breast cancer risk by 38% but does not increase the risk of endometrial cancer, the same as Tamoxifene which - although reduces breast cancer risk by 50% - it doubles the risk of endometrial cancer. Read more ...
